☆ 4.2 Article

Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors

ANNALS OF DIAGNOSTIC PATHOLOGY (2024)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Cell Biology

TROP2, androgen receptor, and PD-L1 status in histological subtypes of high-grade metaplastic breast carcinomas

Suzanne Chartier et al.

Summary: This study retrospectively assessed the clinicopathological characteristics and immunophenotype of 65 patients with high-grade metaplastic breast carcinoma (HG-MBC). It was found that most tumors were triple-negative and had poor response to neoadjuvant chemotherapy, resulting in a worse prognosis. Additionally, there were differences in immunophenotype among different histological subtypes of the tumors. Therefore, tailored therapeutic strategies based on the phenotypic specificities of histological subtypes may improve the outcomes of patients with metaplastic breast carcinoma.

HISTOPATHOLOGY (2023)

添加到收藏夹

Article Oncology

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

Joyce O'Shaughnessy et al.

Summary: This study analyzed the efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC). The results showed that regardless of whether patients had TNBC at initial diagnosis, sacituzumab govitecan improved clinical outcomes. For patients without TNBC at initial diagnosis, the clinical efficacy and safety of sacituzumab govitecan were manageable.

BREAST CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Cell Biology

Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors

David Dum et al.

Summary: TROP2 is expressed in many epithelial neoplasms and is associated with cancer progression in a tumor-type dependent manner.

PATHOBIOLOGY (2022)

添加到收藏夹

Article Biotechnology & Applied Microbiology

TROP2 as Patient-Tailoring but Not Prognostic Biomarker for Breast Cancer

Xiaoyue Liu et al.

Summary: This study investigated the expression levels of TROP2 in Chinese breast cancer patients and explored its value as a biomarker for patient-tailoring and prognosis. The results showed that TROP2 overexpression was significantly associated with the incidence of TNBC. Additionally, the levels of TROP2 expression were correlated with the therapeutic responses to TROP2-directed ADC drugs.

ONCOTARGETS AND THERAPY (2022)

添加到收藏夹

Article Oncology

Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer

Neelima Vidula et al.

Summary: The TACSTD2 gene is expressed in all breast cancer subtypes, particularly luminal A and TNBC, and is correlated with the expression of genes involved in cell epithelial transformation, adhesion, and proliferation. This supports the investigation of TROP2 antibody-drug conjugates in all subtypes of breast cancer.

BREAST CANCER RESEARCH AND TREATMENT (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Correlation of TROP-2 expression with clinical-pathological characteristics and outcome in triple-negative breast cancer

Hava Izci et al.

Summary: Limited data exist regarding the associations between TROP-2 protein expression, clinical-pathological characteristics, and outcome in triple-negative breast cancer (TNBC). This study found that TROP-2 expression is associated with histotype and AR expression, but not with sTILs level and prognostic value in TNBC patients.

SCIENTIFIC REPORTS (2022)

添加到收藏夹

Article Oncology

Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

Yezhe Cheng et al.

Summary: The study aimed to enhance the intratumoral accumulation of an antibody-drug conjugate (ADC) and reduce its off-target toxicity. SKB264, a novel ADC targeting trophoblast antigen 2 (TROP2), showed promising pharmacologic profiles in vitro and in vivo, with stronger targeting effect and better antitumor activity compared to IMMU-132. These findings suggest the potential therapeutic efficacy of SKB264 for TROP2-positive tumors.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance

Jing Zhu et al.

Summary: This study found that the effectiveness of sacituzumab govitecan, a promising drug for breast cancer, could be altered by concomitant treatment. Tamoxifen, in particular, may be a favorable agent for combined therapy.

BREAST CANCER (2022)

添加到收藏夹

Article Oncology

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis

Lisa A. Carey et al.

Summary: Sacituzumab govitecan (SG) improves progression-free survival and overall survival in patients with metastatic triple-negative breast cancer (mTNBC), with manageable safety profile.

NPJ BREAST CANCER (2022)

添加到收藏夹

Article Oncology

Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer

Yeonjin Jeon et al.

Summary: TNBC shows consistent expression of TROP2 regardless of neoadjuvant treatment or primary tumor/metastasis. While the prognostic significance of TROP2 expression in metastatic TNBC has been identified, further evaluation of its predictive value for targeted therapy is needed.

BMC CANCER (2022)

添加到收藏夹

Article Oncology

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

Hope S. Rugo et al.

Summary: The study demonstrates the potential of Sacituzumab govitecan in the treatment of breast cancer, with a longer progression-free survival compared to traditional chemotherapy regimens and a manageable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Trophoblast Cell Surface Antigen 2 (TROP2) as a Predictive Bio-Marker for the Therapeutic Efficacy of Sacituzumab Govitecan in Adenocarcinoma of the Esophagus

Sascha Hoppe et al.

Summary: This study found that TROP2 is widely expressed in esophageal adenocarcinoma and is associated with the treatment response to sacituzumab govitecan. Tumors with high TROP2 expression were more sensitive to SG, while tumors with negative TROP2 expression were not sensitive.

CANCERS (2022)

添加到收藏夹

Article Oncology

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

Mythili Shastry et al.

Summary: Antibody drug conjugates (ADCs) combine the cytotoxicity of chemotherapy and the targeted therapy of antibodies into a single molecule. TROP-2, a transmembrane glycoprotein, is expressed in multiple tumor types, especially in HER2-negative breast tumors, and is associated with worse survival. Sacituzumab govitecan (SG) is a first-in-class TROP-2-directed ADC that has shown significant improvement in progression-free survival and overall survival in pretreated metastatic triple-negative breast cancer. Datopotamab deruxtecan (Dato-DXd) is another TROP-2 ADC that has demonstrated preliminary efficacy in unselected metastatic TNBC. Both SG and Dato-DXd have the potential to deliver enhanced efficacy with reduced toxicity in breast cancer.

BREAST (2022)

添加到收藏夹

Review Oncology

Trop-2 as a Therapeutic Target in Breast Cancer

Elizabeth Sakach et al.

Summary: Trop-2 is a new target for the treatment of breast cancer, with potential therapeutic benefits for metastatic and resistant patients. Inhibitors of Trop-2 have emerged as important treatment options, and ongoing studies investigate combination therapies and its use in early stage disease.

CANCERS (2022)

添加到收藏夹

Article Oncology

Development and characterization of TrMab-6, a novel anti-TROP2 monoclonal antibody for antigen detection in breast cancer

Yusuke Sayama et al.

Summary: The study developed a highly sensitive and specific monoclonal antibody targeting TROP2, demonstrating its effectiveness in detecting TROP2 in breast cancer cells.

MOLECULAR MEDICINE REPORTS (2021)

添加到收藏夹

Article Oncology

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer

Huicheng Liu et al.

Summary: The study developed a bispecific antibody F7AK3 targeting TROP2 and CD3 antigens for TNBC, showing potential antitumor activity in vitro and in vivo by activating T cells against TNBC cells. Further preclinical and clinical evaluation of F7AK3 is warranted for advanced or metastatic TNBC patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

添加到收藏夹

Article Oncology

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Scott T. Tagawa et al.

Summary: Patients with metastatic urothelial carcinoma who have progressed on platinum-based combination chemotherapy and checkpoint inhibitors have limited treatment options with low objective response rates. Sacituzumab govitecan, a TROP-2-targeted antibody-drug conjugate, has shown promising activity in this patient population, with notable efficacy compared to historical controls.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Oncogene-mediated metabolic gene signature predicts breast cancer outcome

Merve Aslan et al.

Summary: This study demonstrated the overexpression of Trop2 in triple-negative breast cancer (TNBC) and the oncogenic role of Trop2 in breast cancer; through metabolic gene signature analysis, a five-gene metabolic signature associated with Trop2 was identified, which significantly predicts poor survival in TNBC patients; the new metabolic gene signature serves as an accurate predictor of breast cancer outcome.

NPJ BREAST CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

A. Bardia et al.

Summary: Patients with metastatic triple-negative breast cancer treated with Sacituzumab govitecan had significantly longer progression-free and overall survival compared to standard chemotherapy, but experienced more frequent myelosuppression and diarrhea as adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Metaplastic breast cancer: Treatment and prognosis by molecular subtype

Jin Hu et al.

Summary: This study found that molecular subtype of breast cancer is not associated with prognosis, and patients can benefit from radiotherapy. However, after receiving radiotherapy, triple-negative patients had superior survival compared to HR-positive or HER2-positive patients.

TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

A. Bardia et al.

Summary: The biomarker analysis from the ASCENT trial demonstrates that sacituzumab govitecan (SG) provides improved survival outcomes and objective response rates in previously treated mTNBC patients with high/medium Trop-2 expression compared to standard-of-care chemotherapy (TPC), regardless of germline BRCA1/2 mutation status. The efficacy outcomes were consistently higher with SG compared to TPC in patients with both high/medium Trop-2 expression and those without germline BRCA1/2 mutations.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Daisuke Okajima et al.

Summary: The novel TROP2-directed antibody-drug conjugate (ADC), datopotamab deruxtecan, showed potent antitumor activity and acceptable safety profiles in preclinical models, suggesting it could be a valuable treatment option for patients with TROP2-expressing tumors.

MOLECULAR CANCER THERAPEUTICS (2021)

添加到收藏夹

Article Oncology

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

James T. Coates et al.

Summary: This study identified mechanisms of resistance to the antibody-drug conjugate (ADC) SG in different metastatic subclones of an individual patient, revealing genomic alterations in both antibody and drug payload targets. Experiments also demonstrated that a TROP2 gene mutation can confer resistance to SG.

CANCER DISCOVERY (2021)

添加到收藏夹

Editorial Material Oncology

Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?

Daniel V. Santi et al.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Oncology

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Emanuele Perrone et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas

Salvatore Lopez et al.

Oncotarget (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan

Burak Zeybek et al.

SCIENTIFIC REPORTS (2020)

添加到收藏夹

Review Oncology

The evolving management of metastatic triple negative breast cancer

Monica K. Malhotra et al.

SEMINARS IN ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: fi nal results from a phase I/II, single-arm, basket trial

K. Kalinsky et al.

ANNALS OF ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Trop2: Jack of All Trades, Master of None

Sara Lenart et al.

CANCERS (2020)

添加到收藏夹

Article Medicine, General & Internal

Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

A. Bardia et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014

Mary C. Schroeder et al.

ONCOLOGIST (2018)

添加到收藏夹

Article

The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

David M. Goldenberg et al.

Oncotarget (2018)

添加到收藏夹

Article Oncology

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer

Aditya Bardia et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-Drug Conjugate for the Treatment of Diverse Epithelial Cancers: Safety and Pharmacokinetics

Allyson J. Ocean et al.

CANCER (2017)

添加到收藏夹

Article Oncology

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

Juan M. Cejalvo et al.

CANCER RESEARCH (2017)

添加到收藏夹

Article Oncology

RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models

Pavel Strop et al.

MOLECULAR CANCER THERAPEUTICS (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis

Ping Zeng et al.

SCIENTIFIC REPORTS (2016)

添加到收藏夹

Article Rehabilitation

A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research

Terry K. Koo et al.

JOURNAL OF CHIROPRACTIC MEDICINE (2016)

添加到收藏夹

Article Oncology

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Alexander N. Starodub et al.

CLINICAL CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)

David M. Goldenberg et al.

ONCOTARGET (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Trop-2 Is a Determinant of Breast Cancer Survival

Federico Ambrogi et al.

PLOS ONE (2014)

添加到收藏夹

Article Oncology

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

A. Goldhirsch et al.

ANNALS OF ONCOLOGY (2013)

添加到收藏夹

Article Pathology

Significantly upregulated TACSTD2 and Cyclin D1 correlate with poor prognosis of invasive ductal breast cancer

Hong Lin et al.

EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Upregulation of Trop-2 quantitatively stimulates human cancer growth

M. Trerotola et al.

ONCOGENE (2013)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Identification of novel targets for breast cancer by exploring gene switches on a genome scale

Ming Wu et al.

BMC GENOMICS (2011)

添加到收藏夹

Review Biochemistry & Molecular Biology

Trop2: A possible therapeutic target for late stage epithelial carcinomas

Rafael Cubas et al.

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2009)

添加到收藏夹

Article Oncology

Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors

HY Huang et al.

CLINICAL CANCER RESEARCH (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.